DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
WALTHAM, Mass., March 06, 2018 -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present at the following upcoming investor conferences:
- Cowen and Company 38th Annual Health Care Conference in Boston, MA on Monday, March 12, 2018 at 12:00 pm ET; and
- Oppenheimer 28th Annual Healthcare Conference in New York, NY on Wednesday, March 21, 2018 at 3:55 pm ET.
About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase, is an investigational drug intended to improve hemodialysis vascular access outcomes. Proteon has completed enrollment in PATENCY-2, a Phase 3 clinical trial evaluating vonapanitase in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis. Proteon is also evaluating vonapanitase in a Phase 1 clinical trial in patients with peripheral artery disease (PAD). For more information, please visit www.proteontx.com.
Investor Contact
George Eldridge, Proteon Therapeutics, Senior Vice President and Chief Financial Officer
781-890-0102
[email protected]
Media Contact
Ann Stanesa, Ten Bridge Communications
617-230-0347
[email protected]
